A randomized trial of intravesical doxorubicin and immunotherapy with bacille calmette-guérin for transitional-cell carcinoma of the bladder Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Transitional Cell
  • Doxorubicin
  • Immunotherapy
  • Mycobacterium bovis
  • Urinary Bladder Neoplasms

abstract

  • As compared with intravesical doxorubicin, immunotherapy with BCG provides improved protection against the recurrence of superficial bladder cancer.

publication date

  • October 24, 1991

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJM199110243251703

PubMed ID

  • 1922207

Additional Document Info

start page

  • 1205

end page

  • 9

volume

  • 325

number

  • 17